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The aim of this systematic review is to summarize the evidence for or against the efficacy of plant food supplements (PFS)
for coping inflammatory conditions by considering epidemiological and human intervention studies. The review considers
six botanical species commonly used as food supplements/medicinals: Urtica dioica L., Symphytum officinalis L., Calendula
officinalis L., Curcuma longa L., Boswellia serrata Roxb., and Harpagophytum procumbens L. The search retrieved 579
publications. By removing the duplicates and applying the inclusion/exclusion criteria, the final number of papers was 47.
No epidemiological data were found. The bibliographic search found no paper regarding the anti-inflammatory effects of
Calendula officinalis L. and Symphytum officinalis L. by oral use. In spite of the long-term traditional use for inflammatory
disorders, Curcuma longa L. and Harpagophytum procumbens L. warrant further investigation, whereas the efficacy of
Urtica dioica L, even if the available data on hard endpoints are promising, requires other trials. Boswellia serrata Roxb.
was found to be the most promising, since it shows the best efficacy for the treatment of pain/inflammatory conditions. In
conclusion, it is advisable to conduct further studies with more homogeneous population and larger number of subjects by
avoiding the heterogeneity of the herbal preparations considered.
Keywords Curcuma longa, boswellia serrata, symphytum officinalis, urtica dioica, harpagophytum procumbens, calendula
officinalis
INTRODUCTION
Inflammation is a complex series of physiological events
designed to repair bodily damage as a result of injury or infec-
tion. The short-term inflammatory response, defined as acute
inflammation, eliminates infections and promotes tissue repair
by activating the innate immune cells (mast cells, leukocytes,
dendrite cells). In humans, cytokine and chemokine levels are
consistently low and typically increase only in response to phys-
iologic stress for attracting the immune cells to the site of injury
and infection. Elevated levels of these cytokines (TNF, IL 1
β etc.) and C reactive protein (CRP) have been studied exten-
sively as predictors of disease and disability in humans. Chronic
inflammation is a critical factor in the pathogenesis of many
disease states including cardiovascular, neurodegenerative and
Address correspondence to Mario Dell’Agli, Ph.D., Universita` degli Studi
di Milano, Department of Pharmacological and Biomolecular Sciences, Via
Balzaretti 9, 20133, Milano, Italy. E-mail: mario.dellagli@unimi.it
Mario Dell’Agli and Chiara Di Lorenzo contributed equally to this paper.
degenerative joint diseases, cancer, and diabetes. It can be con-
sidered the result of a delayed or deregulated inflammation,
which in turn leads to macrophage recruitment along with
T-cells. The byproducts of macrophage activation are toxic
reagents, including reactive oxygen species (ROS), elastase and
other proteases, including cathepsin G, which are responsible
for tissue damage. The body must balance homeostatic state
and response to injury, and mediators of inflammation play a
key role in maintaining this balance.
Over recent times the link between inflammation and nutri-
tion has become increasingly apparent (Pischon et al., 2003;
Zhao et al., 2004; Karin et al., 2006); it has been demonstrated
that an excessive macronutrient intake can contribute to inflam-
matory response as well as some dietary polyphenols are able
to reduce the incidence of cardiovascular mortality and certain
types of cancer due to their anti-inflammatory properties (Lucas
et al., 2011).
PlantLIBRA (PLANT food supplements: Levels of Intake,
Benefit and Risk Assessment) is an EC funded project aiming to
foster the safe use of food supplements containing botanicals or
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their preparations, by evaluating the quality and health benefits
of plant food supplements (PFS), and by increasing science-
based decision-making by regulators and food chain operators.
PlantLIBRA is structured to develop, validate and dissem-
inate data and methodologies for risk and benefit assessment
and implement sustainable international cooperation. Part of the
project is dedicated to the methodology of benefit assessment for
PFS, application and validation. The first step was to review the
evidence for PFS benefits from epidemiological, clinical, and
intervention studies. A number of pathological conditions where
PFS are commonly used were identified and inflammation was
one of those.
The aim of the systematic review is to summarize and
critically evaluate the evidence for or against the efficacy of
PFS or substances (compounds or foods) relevant to PFS for
coping inflammatory conditions. Ten plants were considered:
Olea europea L. (olive), Camellia sinensis L. (as green or
black tea), Vitis vinifera L. (Vine), Boswellia serrata Roxb.
(Indian Frankincense), Matricaria recutita L. (Chamomile),
Symphytum officinalis L. (Comfrey), Calendula officinalis L.
(Marigold), Curcuma longa L. (Turmeric), Urtica dioica L.
(Nettle), and Harpagophytum procumbens L. (Devil’s claw).
The choice of these botanicals in the reviewing process was
based on PlantLIBRA partners’ suggestions and the list of plants
present in Annex 1 of the project.
Epidemiological, human intervention studies using PFS were
then systematically examined and reviewed. The reviewing
work on Olea europea L., Camellia sinensis L., Vitis vinifera
L., and Matricaria recutita L., frequently used as food, is part
of a first publication (submitted to Critical Reviews in Food
Science and Nutrition). This work deals with Urtica dioica L.,
Symphytum officinalis L., Calendula officinalis L., Curcuma
longa L., Boswellia serrata Roxb. ex Colebr., and Harpagophy-
tum procumbens L. botanical species more commonly used as
food supplements/medicinals.
METHODS
Source and Search strategy
Electronic literature searches were conducted using the fol-
lowing databases: Cochrane library, Scifinder Scholar, Embase,
and Pubmed from 1970 to 2010. They were searched for title
and abstract using the following search terms: Latin name of
the plant or common name matched with inflamm∗ or phlo-
gosis or anti-inflammatory. Search limits were human trial and
the English language. Keywords relevant to inflammation (i.e.,
cyclooxygenase, cytokines, adhesion molecules, etc.) were also
used as search terms. Bibliographies of the articles thus located
were scanned for further relevant publications.
For collecting epidemiological studies, the same terms were
used for searching title, abstract, and index terms for the six
PFS (1) and for health area inflammation (2). Terms used for
searching epidemiological studies (3) were: epidemiology/exp
or epidemiolog∗ or case control or cohort. We selected epi-
demiological studies for applicable PFS and inflammation in
two different ways and then merged the results: (1) and (2)
filtered by study type or (1) and (2) and (3).
Inclusion and Exclusion Criteria
Controlled human studies performed on healthy/unhealthy
populations were included. Randomization, even if preferable,
was not considered essential. Inclusion criteria were the use
of PFS as food, pill/powder/extract, etc. Among the evaluation
criteria, it was considered of relevance the presence of these
data, such as botanical name of the plants, the used preparation
as extract, tincture, decoction, infusion, etc., and the daily intake.
Publications reporting incomplete qualitative and quantitative
analysis of PFS were flagged but not excluded. Studies reporting
co-treatments with other PFS or other bioactive compounds
were included. Studies where general foodstuffs were fortified
with PFS or studies reporting on individual compounds were
not considered.
Other criteria of exclusion were: the use of botani-
cals for cosmetic, homeopathy, aromatherapy, topical use,
aerosol/inhalation, and hygiene products (toothpaste, mouth
rinse, etc). Publications regarding reviews, commentary, letters
to the Editor, and patents were not considered. Similar inclu-
sion/exclusion criteria were used for epidemiological studies.
From the bulk of papers selected by the search strategy de-
scribed above, those not fulfilling the inclusion criteria were
excluded by reading the abstract. For remaining studies, a cus-
tomized version of the extraction database was used.
Data Extraction
A database (written in MS Access) was designed and im-
plemented to aid the data extraction process. Publications were
checked for duplicates, read in full by two authors, and sub-
jected to the in/out process following the inclusion/exclusion
criteria described above. Ten percent of the publications found
were checked by a second reviewer and compared, whereas
5% of the publications not excluded by the in/out procedure
were checked by a second reviewer and compared. Papers were
stored in a reference manager (Endnote X1.0.3). A pdf file of
each publication was retrieved.
Quality Assessment
The methodological quality of the studies was indepen-
dently evaluated by two reviewers (MDA and CDL) using
the Jadad score (Jadad et al., 1996). Particular attention was
given to the presence of adequate statistical analysis and a well-
characterized experimental design; other quality assessment cri-
teria were based on the recommendations from The Cochrane
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Handbook of Systematic Reviews of Interventions (Cochrane
Collaboration, 2008) and from CONSORT statement for herbal
medicine (Gagnier et al., 2006). The same criteria were used for
the quality assessment of epidemiological studies.
RESULTS AND DISCUSSION
Human/Intervention Studies
The search by title and abstract retrieved 579 publications. By
removing the duplicates and applying the inclusion/exclusion
criteria above described, the final number of papers was 47.
These publications were uploaded in the database and the in/out
process lead to 27 publications accepted and used for this sys-
tematic review.
The papers rejected in the in/out sheet process were excluded
for the following reasons: (1) the clinical trial was not controlled;
(2) the study was not related to inflammation; (3) the study was
not dealing with the six plants chosen for the systematic review;
(4) the study was performed in vitro or ex vivo; (5) the plant
material was not used as supplement or food; and (6) scientific
quality was considered insufficient.
According to ESCOP the indication of use of Marigold is
for the treatment of minor inflammations of the skin and mu-
cosa. Several national authorities recommend Comfrey only for
external use due to the presence of pyrrolizidine alkaloids. Ac-
cordingly, the bibliographic search found no paper regarding
the anti-inflammatory effects of Marigold and Comfrey by oral
use. Table 1 reports the preparations used for clinical trials, the
active principles identified, and the daily intake of the publi-
cations considered in the present review. Fifty percent of the
studies give the precise composition/concentration of the ac-
tive principle in the pharmaceutical form used for the clini-
cal study. The majority of the studies with Boswellia serrata
Roxb. ex Colebr reported the analytical composition of the ac-
tive principle, whereas for Urtica dioica L., any information
was given. Tables 2–5 report the human trials related to Urtica
dioica L., Harpagophytum procumbens L., Curcuma longa L.,
and Boswellia serrata Roxb. ex Colebr. For each PFS, the publi-
cations are listed in two columns: benefit/no benefit, depending
on whether the study reported beneficial/nonbeneficial results.
The change of biomarkers or hard endpoints (a symptom or
the change of a physiological state) was used as a criterion by
which a publication is listed under the “benefit” or “no benefit”
column.
Urtica Dioica L.
Urtica dioica L. is listed in Deutsches Arzneibuch or Pharma-
copoea Helvetica and ESCOP monographs as leaf, herb (dried
flowering part), or dried rhizomes and roots. Four publications
on Nettle met the inclusion/exclusion criteria and three out of
four were accepted for the present systematic review: the leaves
were used in one study, the freeze-dried herb in gelatin capsules
in the second, and the third was performed to test Phytalgic R©,
an association of Urtica dioica L. (the part of the plant used
was not specified), fish oil rich in omega-3 and omega-6 fatty
acids, zinc, and vitamin E. The results are reported in Table 2.
Chrubasik et al. (1997) measured C reactive protein and evalu-
ated the response to pain by WOMAC test in 36 subjects with
acute arthritis finding no effect. In studies reporting hard end-
points, the number of subjects reporting benefits was 150 vs. 36
subjects with no benefits. A positive response was seen on rhini-
tis (Mittman, 1990), pain (Jacquet et al., 2009), and the physical
impairment caused by arthritis (Chrubasik et al., 1997). The de-
crease of the intake of analgesic drugs (Jacquet et al., 2009) was
another parameter to assess beneficial effects. Thus, the search
has clearly evidenced a highly limited documentation and the
paucity of the number of subjects. Even if the available data
on hard endpoints are promising, the assessing of the efficacy
requires other trials.
Harpagophytum Procumbens L.
Devil’s claw root consists of the cut and dried tuberous, sec-
ondary roots of Harpagophytum procumbens L. Six studies were
included. One study (Moussard et al., 1992) recruited 25 partic-
ipants and reported no effect of Devil’s claw on inflammatory
biomarkers (PGE2, TXB2, LTB4, and 6-keto-PGF1α) (Table 3).
The lack of inhibitory effect of devil’s claw on the biosynthesis
of prostanoids was interpreted as positive, since adverse effects
commonly associated with NSAIDs are not to be expected with
the use of Harpagophytum procumbens. In the studies (n = 5)
evaluating hard endpoints, a positive response was observed:
502 subjects showed benefits for chronic low back pain and
disability due to osteoarthritis of knee. Several studies, which
failed to meet the inclusion criteria for this systematic review,
tend to point for the effectiveness of Harpagophytum procum-
bens to treat conditions maintained by inflammatory processes.
However, two systematic reviews (Gagnier et al., 2006; Gagnier
et al., 2007) of randomized controlled clinical studies of herbal
medicines for low back pain reported contradictory results: ei-
ther strong evidence, moderate evidence, or no significant differ-
ence with respect to placebo for the treatment of acute episodes
of chronic low back pain with devil’s claw extract. Thus, this
topic urges welldesigned studies, also for the lack of epidemi-
ological studies. In spite of the long-term traditional use of this
plant in Southern Africa for inflammatory disorders, the existing
data warrant further investigation.
Curcuma Longa L.
Turmeric consists of the scalded and dried rhizomes of Cur-
cuma longa L. The majority of the studies were performed using
extracts rich in curcuminoids or curcumin that are considered
the active principles of turmeric; the use of the rhizome as a
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Table 2 Urtica dioica L.
No benefit Benefit Comments
N◦ studies N◦ participants N◦ studies N◦ participants Efficacy
Biomarkers
C reactive protein (CRP) 1 (Chrubasik et al., 1997) 36 OSN∗
TOTAL 1a 36b 0c 0d
Hard endpoints
Physical impairment score in arthritis 1 (Chrubasik et al., 1997) 36
Decrease in intake of analgesic drugs 1 (Jacquet et al., 2009) 81 OSN
Pain (WOMAC test) 1 (Chrubasik et al., 1997) 36 1 (Jacquet et al., 2009) 81 OSN
Overall rating of treatment (rhinitis) 1 (Mittman, 1990) 69 OSN
TOTAL 1a 36b 2c 150d
∗Other studies needed.
aNumber of studies where the effect was not observed.
bThe total number of subjects recruited in the studies which reported no benefit.
cNumber of studies where the effect was observed.
dThe total number of subjects recruited in the studies which reported benefit.
tincture is documented in only one study (Hamblin et al., 2008).
The two studies included were performed using Curcuma longa
L. in combination with Boswellia serrata Roxb. (Houssen et al.,
2010).
The in/out process selected eight studies. Those (n = 4) inves-
tigating the effect on inflammatory biomarkers concluded that
the treatment reduced TNF, IL-6, nitric oxide, LTC4, and MDA
(Table 4). Conversely, ESR (erythrocyte sedimentation rate) did
not change following turmeric treatment (Kulkarni et al., 1991);
the efficacy of the treatment was considered convincing only for
MDA, since all studies (n = 3) gave positive results (altogether
155 participants). The total number of subjects recruited in the
studies (n = 5) showing positive results on hard endpoints was
256 versus 213 in the studies with no benefits (n = 4). At this
stage, the number of studies is insufficient for supporting the
claim of the anti-inflammatory activity of turmeric. Validation
for the use of turmeric deserves further studies.
Boswellia Serrata Roxb. Ex Colebr
Indian Frankincense (salai guggal) is the oleo-gum resin of
Boswellia serrata Roxb. ex Colebr used in Ayurvedic system of
medicine for degenerative joint diseases.
The search retrieved seven publications reporting the posi-
tive effect of Boswellia serrata on several biomarkers such as
nitric oxide, MDA, LTC4, metalloprotease-3, eosinophils count,
leukocyte infiltration, etc. (Table 5); conversely, controversial
Table 3 Harpagophytum procumbens L
No benefit Benefit Comments
N◦ studies N◦ participants N◦ studies N◦ participants Efficacy
Biomarkers
PGE2 1 (Moussard et al., 1992) 34 OSN∗
Thromboxane 1 (Moussard et al., 1992) 34 OSN
6-keto-PGF1α 1 (Moussard et al., 1992) 34 OSN
LTB4 1 (Moussard et al., 1992) 34 OSN
TOTAL 1a 34b 0c 0d
Hard endpoints
Pain in osteoarthritis of the knee 1 (Chantre et al., 2000)# 122 OSN
Disability in osteoarthritis of the knee 1 (Chantre et al., 2000)# 122 OSN
Chronic low back pain 4 (Chrubasik et al., 1996);(Chrubasik
et al., 1999);(Chrubasik et al.,
2003);(Chrubasik et al., 2005)
380 YES
Reduction of NSAIDs intake 1 (Chantre et al., 2000)# 122 OSN
TOTAL 0a 0b 5c 502d
∗Other studies needed.
#Also published as (Leblan et al., 2000).
aNumber of studies where the effect was not observed.
bThe total number of subjects recruited in the studies which reported no benefit.
cNumber of studies where the effect was observed.
dThe total number of subjects recruited in the studies which reported benefit.
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Table 4 Curcuma longa L.
No benefit Benefit Comments
N◦ studies N◦ participants N◦ studies N◦ participants Efficacy
Biomarkers
MDA 3 (Durgaprasad et al., 2005);(Houssen
et al., 2010); (Usharani et al., 2008)
155 YES
Leukotriene C4 1 (Houssen et al., 2010) 63 OSN∗
Nitric oxide 1 (Houssen et al., 2010) 63 OSN
ESR (erythrocyte
sedimentation rate)
1 (Kulkarni et al., 1991) 42 OSN
TNF 1 (Usharani et al., 2008) 72 OSN
IL-6 1 (Usharani et al., 2008) 72 OSN
TOTAL 1a 42b 3c 155d
Hard end-points
Pain 1 (Durgaprasad et al., 2005) 20 3 (Satoskar and Shenoy, 1986);(Hamblin
et al., 2008);(Kulkarni et al., 1991)
107 YES
CAI (Clinical
Index Activity)
1 (Hanai et al., 2006) 89 OSN
Oral lichen planus 1 (Chainani-Wu et al., 2007) 33 OSN
EI (Endoscopic Index) 1 (Hanai et al., 2006) 89 OSN
Tenderness 1 (Satoskar and Shenoy, 1986) 45 OSN
Cord oedema 1 (Satoskar and Shenoy, 1986) 45 OSN
Disability score 1 (Kulkarni et al., 1991) 42 OSN
Joint score 1 (Kulkarni et al., 1991) 42 OSN
Duodenal ulcer 1 (Van Dau et al., 1998) 118 OSN
Gastric ulcer 1 (Kositchaiwat et al., 1993) 60 OSN
TOTAL 4a 213b 5c 256d
∗Other studies needed.
aNumber of studies where the effect was not observed.
bThe total number of subjects recruited in the studies which reported no benefit.
cNumber of studies where the effect was observed.
dThe total number of subjects recruited in the studies which reported benefit.
results were observed for ESR and the leukocyte count. How-
ever, at an overall view, six studies reported benefits, with a total
number of subjects much higher with respect to the number of
subjects showing no benefits (308 vs. 72). The number of sub-
jects participating to the nine studies showing positive results
on hard endpoints was 443 versus 82 subjects in the two studies
with no benefits. Pain is the symptom, which seems to better re-
spond to the treatment: 353 subjects in seven studies witnessed
a reduction of pain after treatment.
Ernst (2008) carried out a systematic review from all random-
ized clinical trials with Boswellia serrata extracts and concluded
that the evidence for the effectiveness is encouraging, but not
compelling.
Epidemiology Studies
The bibliographic search retrieved 38 papers for Boswellia
serrata Roxb.; 23 for Harpagophytum procumbens L. and Urtica
dioica L.; 16 for Symphytum officinalis L.; 12 for Curcuma
longa L.; and 8 for Calendula officinalis L. By application of
the exclusion criteria, no epidemiological studies were accepted
through the in/out process.
Conclusive Remarks and Future Work
The aim of this systematic review was to evaluate efficacy
of PFS against inflammation and to direct researchers, Health
Authorities, and decision makers/opinion leaders about future
research for the purpose of making claims on product labels or in
promotional material. This work represents the second part (see
previous submission) of a reviewing process of studies (clinical,
intervention, and epidemiological) performed with PFS derived
from plants known for their use in inflammatory conditions.
With the exclusion of Boswellia serrata for all the botanicals
considered in this review, an ESCOP monograph exists with the
indication for use (ESCOP, 2009). Marigold is indicated for the
treatment of minor inflammation of the skin and mucosa and
for healing of minor wounds, and the oral use is not considered.
Then the use of Marigold as PFS has to be fully investigated.
Comfrey should not be consumed as food supplement for the
presence of toxic pyrrolizidine alkaloids. In Germany, Comfrey
is restricted to external use (Stickel and Seitz, 2000) and daily
dose is limited to a maximum of 100 μg per day. A considerable
fraction of externally applied pyrrolizidine alkaloids is absorbed
through the skin (0.1–0.4%) and has been detected in urine (Lin
et al., 1998). Turmeric is indicated for mild digestive complaints
and minor biliary dysfunction. Only devil’s claw and nettle
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Table 5 Boswellia serrata Roxb
No benefit Benefit Comments
N◦ studies N◦ participants N◦ studies N◦ participants Efficacy
Biomarkers
Leukocyte infiltration 1 (Gupta et al., 1997) 50 OSN∗
Number of leukocytes 1 (Gupta et al., 2001) 30 1 (Gupta et al., 1997) 50 OSN
Eosinophils 2 (Gupta et al., 1998); (Gupta et al., 2001) 70 OSN
ESR (Erythrocyte
Sedimentation Rate)
1 (Kulkarni et al., 1991) 42 2 (Gupta et al., 1998); (Usha and Naidu,
2006a)
100 OSN
Leukotriene C4 1 (Houssen et al., 2010) 63 OSN
MDA 1 (Houssen et al., 2010) 63 OSN
Nitric oxide 1 (Houssen et al., 2010) 63 OSN
MMP-3 1 (Sengupta et al., 2008) 65 OSN
TOTAL 2a 72b 6c 308d
Hard endpoints
Pain 7 (Usha and Naidu, 2006b); (Kulkarni
et al., 1991); (Gupta et al., 1997);
(Sengupta et al., 2008); (Sengupta
et al., 2010); (Sontakke et al., 2007);
(Kimmatkar et al., 2003)
353 YES
Ulcerations 1 (Gupta et al., 1997) 50 OSN
Properties of stools 1 (Gupta et al., 2001) 30 OSN
Disability score 1 (Kulkarni et al., 1991) 42 OSN
Joint score 1 (Kulkarni et al., 1991) 42 1 (Usha and Naidu, 2006a) 60 OSN
Knee circumference 1 (Usha and Naidu, 2006b) 40 OSN
TOTAL 2a 82b 9c 443d
∗Other studies needed.
aNumber of studies where the effect was not observed.
bThe total number of subjects recruited in the studies which reported no benefit.
cNumber of studies where the effect was observed.
dThe total number of subjects recruited in the studies which reported benefit.
leaf/herb have indications for the treatment of degenerative joint
disorders.
The conditions, against which the PFS discussed in the
present review were employed included osteoarthritis, chronic
low back pain, and ulcer.
The outcome of the evaluation process indicates the need of
well designed randomized controlled trials for Urtica dioica,
Harpagophytum procumbens, and Boswellia serrata. For these
botanicals, although the studies are insufficient, all outcomes
support for a positive effect. Conversely, Curcuma longa does
not seem to affect significantly inflammatory conditions. Even
though some inflammatory biomarkers were reduced by the
treatment, the effect on hard endpoints does not show a signifi-
cant difference between subjects reporting benefits and subjects
with no benefits.
Major drawbacks hampering the assessment of the beneficial
health effect are insufficient characterization of PFS and hetero-
geneity in dosing and time of exposure between studies, small
sample size and incomplete reporting of data (see Table 1). Little
independent replication was found. If any information is given
about the phytochemical composition of a preparation and the
content of the active ingredient, it is difficult to evaluate the
efficacy of the plant or to distinguish between a placebo effect
and the actual effect due to the active ingredient when properly
dosed.
Where it is possible to identify likely active components
within PFS, these levels should be reported to allow for fu-
ture stratified meta-analysis. Interventions should be carried out
over a timescale sufficient to observe a change in the endpoint
measured. Studies must be controlled for the full length of the
intervention, and the placebo effect must be included. The use
of solely positive controls where a high placebo effect might
be reasonably expected could be considered misleading. The
metabolism of suspected active ingredients must be considered
during study design, randomization, and analysis. The use of an
adequate statistical analysis must be considered as a priority to
evaluate the good quality of the work.
In conclusion, in the future, it is advisable to conduct studies
with more homogeneous population and larger number of sub-
jects by avoiding the heterogeneity of the herbal preparations
considered.
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